Skip to Content

Generic Bevyxxa Availability

Bevyxxa is a brand name of betrixaban, approved by the FDA in the following formulation(s):

BEVYXXA (betrixaban - capsule;oral)

  • Manufacturer: PORTOLA PHARMS INC
    Approval date: June 23, 2017
    Strength(s): 40MG [RLD], 80MG [RLD]

Has a generic version of Bevyxxa been approved?

No. There is currently no therapeutically equivalent version of Bevyxxa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bevyxxa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Benzamides and related inhibitors of factor Xa
    Patent 6,376,515
    Issued: April 23, 2002
    Inventor(s): Bing-Yan; Zhu & Penglie; Zhang & Lingyan; Wang & Wenrong; Huang & Erick A.; Goldman & Wenhao; Li & Jingmei; Zuckett & Yonghong; Song & Robert M.; Scarborough
    Assignee(s): COR Therapeutics, Inc.
    Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Patent expiration dates:
    • September 15, 2020
      ✓ 
      Patent use: PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF PULMONARY EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF VENOUS THROMBOSIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Benzamides and related inhibitors of factor Xa
    Patent 6,835,739
    Issued: December 28, 2004
    Inventor(s): Bing-Yan; Zhu & Penglie; Zhang & Lingyan; Wang & Wenrong; Huang & Erick A.; Goldman & Wenhao; Li & Jingmei; Zuckett & Yonghong; Song & Robert M.; Scarborough
    Assignee(s): Millennium Pharmaceuticals, Inc.
    Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Patent expiration dates:
    • September 15, 2020
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical salts and polymorphs of a factor Xa inhibitor
    Patent 7,598,276
    Issued: October 6, 2009
    Inventor(s): Grant; Craig & Kanter; James P. & Langlands; Graeme
    Assignee(s): Millenium Pharmaceuticals, Inc.
    The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.
    Patent expiration dates:
    • November 8, 2026
      ✓ 
      Drug substance
  • Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
    Patent 8,404,724
    Issued: March 26, 2013
    Assignee(s): Millennium Pharmaceuticals, Inc.
    Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.
    Patent expiration dates:
    • March 29, 2031
      ✓ 
      Patent use: INHIBITING COAGULATION
      ✓ 
      Drug product
  • Benzamides and related inhibitors of factor XA
    Patent 8,518,977
    Issued: August 27, 2013
    Assignee(s): Millennium Pharmaceuticals, Inc.
    Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Patent expiration dates:
    • September 15, 2020
      ✓ 
      Drug substance
  • Methods of using crystalline forms of a salt of a factor Xa inhibitor
    Patent 8,557,852
    Issued: October 15, 2013
    Assignee(s): Millennium Pharmaceuticals, Inc.
    The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa.
    Patent expiration dates:
    • September 8, 2028
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
    • September 8, 2028
      ✓ 
      Patent use: PROPHYLAXIS OF VENOUS THROMBOSIS
  • Benzamides and related inhibitors of factor Xa
    Patent 8,691,847
    Issued: April 8, 2014
    Assignee(s): Millennium Pharmaceuticals, Inc.
    Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Patent expiration dates:
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • September 15, 2020
      ✓ 
      Patent use: PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Methods of synthesizing factor Xa inhibitors
    Patent 8,987,463
    Issued: March 24, 2015
    Assignee(s): Millennium Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc.
    Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.
    Patent expiration dates:
    • December 28, 2030
      ✓ 
      Drug product
  • Pharmaceutical salts and polymorphs of a factor Xa inhibitor
    Patent 9,555,023
    Issued: January 31, 2017
    Assignee(s): Millennium Pharmaceuticals, Inc.
    The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.
    Patent expiration dates:
    • November 7, 2026
      ✓ 
      Patent use: PROPHYLAXIS OF PULMONARY EMBOLISM
  • Benzamides and related inhibitors of factor XA
    Patent 9,629,831
    Issued: April 25, 2017
    Assignee(s): Millennium Pharmaceuticals, Inc.
    Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Patent expiration dates:
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF VENOUS THROMBOSIS
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
    • September 15, 2020
      ✓ 
      Patent use: PROPHYLAXIS OF PULMONARY EMBOLISM

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 23, 2022 - NEW CHEMICAL ENTITY
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide